From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.
We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.
Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.
we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions